Bcl-2 expression has been confirmed in 20% to 58% of NSCLC and 32% to 69.4% of squamous cell carcinomas of the lung [19,22,28] and this is consistent with our findings of 50% and 51% Bcl-2 positive NSCLC tumors and 62% and 63% positive squamous cell carcinomas for the training and validation cohorts respectively. The gene discussed is BCL2; the disease is squamous cell lung carcinoma.